Moderna Loses Key Defense in Northwestern LNP Patent Fight
MRNA has more than doubled off its 52-week low of $22.28.
Summary
A Delaware federal judge rejected Moderna's argument that the Bayh-Dole Act shields it from Northwestern University's patent infringement claims over lipid nanoparticle (LNP) technology used in its COVID-19 vaccine Spikevax. The ruling does not decide infringement or Moderna's other defenses, but it removes a significant legal shield and keeps the 2024 lawsuit on track toward trial. This is part of a broader web of high-stakes LNP patent litigation involving Moderna, Pfizer, and others. The decision increases Moderna's litigation risk and potential damages exposure, though no financial impact has been quantified. Watch for further rulings on Moderna's remaining defenses and any settlement discussions.
At the time of this announcement, MRNA was trading at $198.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.1B. The 52-week trading range was $22.28 to $208.90. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.